The Role of Lithium-Ion Batteries in the Growing Trend of Electric Vehicles.

Within the automotive field, there has been an increasing amount of global attention toward the usability of combustion-independent electric vehicles (EVs). Once considered an overly ambitious and costly venture, the popularity and practicality of EVs have been gradually increasing due to the usage of Li-ion batteries (LIBs). Although the topic of LIBs has been extensively covered, there has not yet been a review that covers the current advancements of LIBs from economic, industrial, and technical perspectives. Specific overviews on aspects such as international policy changes, the implementation of cloud-based systems with deep learning capabilities, and advanced EV-based LIB electrode materials are discussed. Recommendations to address the current challenges in the EV-based LIB market are discussed. Furthermore, suggestions for short-term, medium-term, and long-term goals that the LIB-EV industry should follow are provided to ensure its success in the near future. Based on this literature review, it can be suggested that EV-based LIBs will continue to be a hot topic in the years to come and that there is still a large amount of room for their overall advancement.

Development of homogeneous 384-well high-throughput screening assays for Abeta1-40 and Abeta1-42 using AlphaScreen technology.

Amyloid beta (Abeta) peptides are the major constituent of amyloid plaques, one of the hallmark pathologies of Alzheimer's disease. Accurate and precise quantitation of these peptides in biological fluids is a critical component of Alzheimer's disease research. The current most established assay for analysis of Abeta peptides in preclinical research is enzyme-linked immunosorbent assay (ELISA), which, although sensitive and of proven utility, is a multistep, labor-intensive assay that is difficult to automate completely. To overcome these limitations, the authors have developed and optimized simple, sensitive, homogeneous 384-well assays for Abeta1-42 and Abeta1-40 using AlphaScreen technology. The assays are capable of detecting Abeta peptides at concentrations <2 pg/mL and, using a final assay volume of 20 microL, routinely generate Z' values >0.85. The AlphaScreen format has the following key advantages: substantially less hands-on time to run, easier to automate, higher throughput, and less expensive to run than the traditional ELISA. The results presented here show that AlphaScreen technology permits robust, efficient, and cost-effective quantitation of Abeta peptides.